bluebird bio Inc (NAS:BLUE)
$ 0.6078 0.0338 (5.89%) Market Cap: 117.15 Mil Enterprise Value: 240.01 Mil PE Ratio: 0 PB Ratio: 0.29 GF Score: 25/100

bluebird bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 01:40PM GMT
Release Date Price: $44.23 (+2.32%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're pleased to have bluebird bio with us. From the company, we have Chip Baird, Chief Financial Officer; Philip Gregory, Chief Scientific Officer; and Joanne Smith-Farrell, Chief Business Officer and Head of Oncology.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And with that, to kick it off, maybe we could start with kind of a big picture question here. Given that you're in fields here, both on the rare disease side, then on the oncology side with genomic medicine, that face a relatively steep curve of innovation and optimization, as you look at portfolio management, how do you position your drug and technology portfolio to stay at the forefront as you look forward?

William D. Baird
bluebird bio, Inc. - CFO

Salveen, so I'll start there and ask Philip and Joanne to comment as well. But wanted to maybe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot